PDE1A基因常见变异与中国2型糖尿病患者冠心病相关,有助于个体化治疗目标及心血管并发症风险分层
在中国2型糖尿病患者中开展两阶段全基因组关联研究(3596例冠心病患者和8898例对照),并在欧洲2型糖尿病患者及一般人群中复制。在PDE1A基因发现与冠心病和血压相关的新变异rs10171703,该变异与血压达标(130/80 mmHg)交互影响冠心病和心肌梗死风险,不同基因型患者对血压控制的反应存在差异。
要点
- 在中国2型糖尿病患者中,PDE1A基因变异rs10171703与冠心病(OR 1.21,95%CI 1.13-1.30)及血压相关。
- 该变异与血压达标(130/80 mmHg)交互影响冠心病(P交互=0.0155)和心肌梗死(P交互=5.1×10⁻⁴)风险。
- CC基因型患者血压控制后心血管事件风险降低超过40%,TT基因型患者心肌梗死风险增加三倍。
核心结论
- 在中国2型糖尿病患者中发现PDE1A基因上与冠心病和血压相关的新变异,该变异与血压达标交互作用,对冠心病风险产生不同影响。
- 整合该信息可能有助于糖尿病精准医疗的个体化治疗策略,但仅在研究结果得到验证时。
研究设计与样本
- 两阶段全基因组关联研究,中国2型糖尿病患者3596例冠心病和8898例对照。
- 在欧洲2型糖尿病患者(764例冠心病和4276例对照)及一般人群(n=51442-547261)中进行复制。
主要发现
- 在中国2型糖尿病患者中鉴定出PDE1A基因变异rs10171703与冠心病相关(OR 1.21,95%CI 1.13-1.30;P=2.4×10⁻⁸)及与血压相关(β±SE 0.130±0.017;P=4.1×10⁻¹⁴),但在一般人群中仅呈适度关联。
- 该变异与血压达标(130/80 mmHg)交互影响冠心病(P交互=0.0155)和心肌梗死(P交互=5.1×10⁻⁴)。
- rs10171703 CC基因型患者血压控制后心血管事件风险降低超过40%(2.9×10⁻⁸<P<3.6×10⁻⁵),CT基因型患者无差异(0.0726<P<0.2614),TT基因型患者心肌梗死风险增加三倍(P=6.7×10⁻³)。
临床怎么用
- 原文结论指出,整合该变异信息可能有助于糖尿病精准医疗的个体化治疗策略,但仅在研究结果得到验证时。
局限性
- 原文结论强调,整合该信息可能有助于个体化治疗策略,但仅在研究结果得到验证时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study we aim to unravel genetic determinants of coronary heart disease (CHD) in type 2 diabetes (T2D) and explore their applications. RESEARCH DESIGN AND METHODS: We performed a two-stage genome-wide association study for CHD in Chinese patients with T2D (3,596 case and 8,898 control subjects), followed by replications in European patients with T2D (764 case and 4,276 control subjects) and general populations (n = 51,442-547,261). Each identified variant was examined for its association with a wide range of phenotypes and its interactions with glycemic, blood pressure (BP), and lipid controls in incident cardiovascular diseases. RESULTS: We identified a novel variant (rs10171703) for CHD (odds ratio 1.21 [95% CI 1.13-1.30]; P = 2.4 × 10-8) and BP (β ± SE 0.130 ± 0.017; P = 4.1 × 10-14) at PDE1A in Chinese T2D patients but found only a modest association with CHD in general populations. This variant modulated the effects of BP goal attainment (130/80 mmHg) on CHD (Pinteraction = 0.0155) and myocardial infarction (MI) (Pinteraction = 5.1 × 10-4). Patients with CC genotype of rs10171703 had >40% reduction in either cardiovascular events in response to BP control (2.9 × 10-8 < P < 3.6 × 10-5), those with CT genotype had no difference (0.0726 < P < 0.2614), and those with TT genotype had a threefold increase in MI risk (P = 6.7 × 10-3). CONCLUSIONS: We discovered a novel CHD- and BP-related variant at PDE1A that interacted with BP goal attainment with divergent effects on CHD risk in Chinese patients with T2D. Incorporating this information may facilitate individualized treatment strategies for precision care in diabetes, only when our findings are validated.
引用
- Tam CHT, Lim CKP, Luk AOY, et al. Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes. Diabetes Care. 2023. PMID: 37125963. doi:10.2337/dc22-2331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。